Clinical Trial Update: Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) [Phase 2]

View source ↗

Summary

An update on the EMERGE Phase 2 trial evaluating epigenetic modulation to boost the immune response in gastrointestinal cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Cancer, GI Cancer | Phase 2 | Status: UNKNOWN